Phase III randomized study of radiotherapy plus procarbazine, lomustine, and vincristine with or without BUdR for treatment of anaplastic astrocytoma: final report of RTOG 9404.
about
Exciting new advances in neuro-oncology: the avenue to a cure for malignant gliomaManagement of treatment-associated toxicites of anti-angiogenic therapy in patients with brain tumors.Angiogenic inhibition in high-grade gliomas: past, present and future.CyberKnife enhanced conventionally fractionated chemoradiation for high grade glioma in close proximity to critical structures.Advanced MR imaging of gliomas: an updateRecurrent high-grade glioma: a diagnostic and therapeutic challenge.An orthotopic glioblastoma mouse model maintaining brain parenchymal physical constraints and suitable for intravital two-photon microscopy.An ESR and DFT study of hydration of the 2'-deoxyuridine-5-yl radical: a possible hydroxyl radical intermediate.Ethynyldeoxyuridine (EdU) suppresses in vitro population expansion and in vivo tumor progression of human glioblastoma cells.CNS Anticancer Drug Discovery and Development Conference White Paper.Radiotherapy and temozolomide for anaplastic astrocytic gliomas.Bevacizumab in high-grade gliomas: a review of its uses, toxicity assessment, and future treatment challenges.Stereotactic radiosurgery: adjacent tissue injury and response after high-dose single fraction radiation. Part II: Strategies for therapeutic enhancement, brain injury mitigation, and brain injury repair.Bromodeoxyuridine inhibits cancer cell proliferation in vitro and in vivo.Motexafin gadolinium: a novel radiosensitizer for brain tumors.Intravascular thrombosis in central nervous system malignancies: a potential role in astrocytoma progression to glioblastomaSix-color intravital two-photon imaging of brain tumors and their dynamic microenvironment.Antiangiogenic therapies for high-grade glioma.Emerging clinical principles on the use of bevacizumab for the treatment of malignant gliomas.Enhancing radiation therapy for patients with glioblastoma.End-of-life symptoms and care in patients with primary malignant brain tumors: a systematic literature review.The role of cytotoxic chemotherapy in the management of progressive glioblastoma : a systematic review and evidence-based clinical practice guideline.Targeting adaptive glioblastoma: an overview of proliferation and invasion.Imaging parameters of high grade gliomas in relation to the MGMT promoter methylation status: the CT, diffusion tensor imaging, and perfusion MR imaging.Anaplastic astrocytoma: prognostic factors and survival in 4807 patients with emphasis on receipt and impact of adjuvant therapy.Electrophilic 5-Substituted Uracils as Potential Radiosensitizers: A Density Functional Theory Study.Combination of 6-thioguanine, capecitabine, and celecoxib with temozolomide or lomustine for recurrent high-grade glioma.Impact of provider level, training and gender on the utilization of palliative care and hospice in neuro-oncology: a North-American survey.Antiangiogenic therapy for patients with recurrent and newly diagnosed malignant gliomas.Combined modality approaches in the management of adult glioblastoma.Electron stimulated desorption of anions from native and brominated single stranded oligonucleotide trimers.Integration of palliative care into the neuro-oncology practice: patterns in the United States.Anaplastic astrocytomas: biology and treatment.Formation of pyrimidine-pyrimidine type DNA intrastrand cross-links: a theoretical verification.The prognostic value of IDH mutations and MGMT promoter status in secondary high-grade gliomas.Expression pattern and prognostic significance of IGFBP isoforms in anaplastic astrocytoma.Development of a transplantable glioma tumour model from genetically engineered mice: MRI/MRS/MRSI characterisation.Electron induced single strand break and cyclization: a DFT study on the radiosensitization mechanism of the nucleotide of 8-bromoguanine.Retrospective study of dasatinib for recurrent glioblastoma after bevacizumab failure.Contemporary Review of the Management of Brain Metastasis with Radiation
P2860
Q24632791-FA1ABD88-B428-4564-B67B-5E607C5E4FECQ30417015-49C6496D-85D1-4C07-9069-7D770FB4A079Q30455596-2E97B73B-0078-4DA9-B2A7-C1CA759AB589Q30480933-826E6F01-55BF-409A-B72C-40C23D864980Q30655700-1D89BF91-FADB-47DB-874C-0DC2E7FBEEB0Q33864058-061A50E8-A748-4664-8446-A6ACC5A4C140Q34241937-1E97850B-F7EB-4A06-94DA-1F3AF7B8C61DQ34422134-0D183277-2864-4A7D-A851-4D4EA7A46B8CQ35457074-6C579EA4-5414-4747-91E2-D64023A70B90Q36089590-E2E0C1B3-9066-4131-8B94-5A86F6565486Q36163603-E9B61AB1-746F-4C65-B1F5-707E390642F1Q36787777-12655F32-9092-4388-B56F-FC03C7F7FE77Q36802285-A5D973FE-3979-4087-9DEB-0FE7F23A4925Q36825162-FED9C424-0633-4491-A867-7D6CFEE55146Q36842747-113E0A40-38C8-41E0-BAF8-29050A9F896BQ37029795-A4C88E66-6FED-45BE-A8D5-94B51C1BBF98Q37599076-3F63864E-09C4-4CE7-99BC-1D33ECE62FACQ37614203-834EE743-FF1E-4717-A460-388835F31CDBQ37766531-F60C25FB-08D0-4855-B741-A1337043AB70Q38101608-B54A2296-AEDC-4287-8492-89869D797E6AQ38187575-969E177D-C4FD-41CE-AFC0-26F5E056A586Q38205133-A31C23E5-36A5-4F05-9E24-B2D5F6C9F399Q38235930-4E3CBD60-807B-44FF-BC5C-4D4E3560C897Q38471533-575FAC51-7D0B-4AF9-B9B6-8617E58ED8AEQ39613251-22656799-0692-4793-81EB-1A5E1ED4344EQ39785770-2B17C19E-D4DA-4E65-822B-D24E2FCF5A57Q41403487-702EA6DF-B50F-45C7-81B7-029E2EAC50EBQ41404126-E7E5CE3C-82F1-499F-837C-DADDC708F83FQ42143173-62B1E629-EEE7-464C-85B1-AF8978EEC2A1Q42151501-64AFD015-523F-48D1-AB88-0FD0D396FA74Q42155797-87693C52-6C18-4F08-BE4F-74694EBC9B98Q43197808-24A421FA-3B7C-4CB5-88CF-BB576042C10DQ46641516-868D47C8-778B-4F52-B669-DD2FD0C72508Q47422882-882CD579-371C-414D-A4A4-DBA4157863A3Q48362177-7E7D36B7-AFA7-4EA1-B953-77E24B8D2101Q48539014-D31F9547-A1A4-499B-A35C-5CF5C8E5BF65Q48665122-214DBC7F-9ED9-4D63-ADBC-58D4475E1281Q53064895-AD429FED-8041-479D-908B-FE2F7CD193ACQ54626874-F3F39847-9A9C-4741-8D8B-EF69CEF3C3EDQ59103143-17642FF0-83BD-493B-9D62-5C1054EB9594
P2860
Phase III randomized study of radiotherapy plus procarbazine, lomustine, and vincristine with or without BUdR for treatment of anaplastic astrocytoma: final report of RTOG 9404.
description
2004 nî lūn-bûn
@nan
2004 թուականի Մարտին հրատարակուած գիտական յօդուած
@hyw
2004 թվականի մարտին հրատարակված գիտական հոդված
@hy
2004年の論文
@ja
2004年論文
@yue
2004年論文
@zh-hant
2004年論文
@zh-hk
2004年論文
@zh-mo
2004年論文
@zh-tw
2004年论文
@wuu
name
Phase III randomized study of ...... ma: final report of RTOG 9404.
@ast
Phase III randomized study of ...... ma: final report of RTOG 9404.
@en
type
label
Phase III randomized study of ...... ma: final report of RTOG 9404.
@ast
Phase III randomized study of ...... ma: final report of RTOG 9404.
@en
prefLabel
Phase III randomized study of ...... ma: final report of RTOG 9404.
@ast
Phase III randomized study of ...... ma: final report of RTOG 9404.
@en
P2093
P1476
Phase III randomized study of ...... ma: final report of RTOG 9404.
@en
P2093
Christopher Schultz
Harry S Greenberg
Howard M Sandler
Jan C Buckner
Michael D Prados
Philip Gutin
Raul Urtasun
Richard Davis
Terrence L Cascino
Theodore Phillips
P304
P356
10.1016/J.IJROBP.2003.08.024
P407
P577
2004-03-01T00:00:00Z